Marine Depsipeptide Nobilamide i Inhibits Cancer Cell Motility and Tumorigenicity via Suppressing Epithelial-Mesenchymal Transition and MMP2/9 Expression

Tu Cam Le, Sultan Pulat, Jihye Lee, Geum Jin Kim, Haerin Kim, Eun Young Lee, Prima F. Hillman, Hyukjae Choi, Inho Yang, Dong Chan Oh, Hangun Kim, Sang Jip Nam, William Fenical

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

A cyclic depsipeptide, nobilamide I (1), along with the known peptide A-3302-B/TL-119 (2), was isolated from the saline cultivation of the marine-derived bacterium Saccharomonospora sp., strain CNQ-490. The planar structure of 1 was elucidated by interpretation of 1D and 2D NMR and MS spectroscopic data. The absolute configurations of the amino acids in 1 were assigned by using the C3 Marfey's analysis and comparing them with those of 2 based on their biosynthetic pathways. Nobilamide I (1) decreased cell motility by inhibiting epithelial-mesenchymal transition markers in A549 (lung cancer), AGS (gastric cancer), and Caco2 (colorectal cancer) cell lines. In addition, 1 modulated the expression of the matrix metalloproteinase (MMP) family (MMP2 and MMP9) in the three cell lines.

Original languageEnglish
Pages (from-to)1722-1732
Number of pages11
JournalACS Omega
Volume7
Issue number2
DOIs
StatePublished - 18 Jan 2022

Bibliographical note

Publisher Copyright:
© 2022 The Authors. Published by American Chemical Society.

Fingerprint

Dive into the research topics of 'Marine Depsipeptide Nobilamide i Inhibits Cancer Cell Motility and Tumorigenicity via Suppressing Epithelial-Mesenchymal Transition and MMP2/9 Expression'. Together they form a unique fingerprint.

Cite this